Opinion|Videos|August 7, 2024
AYA ALL: Pediatric and Adult Inspired Regimens
Focusing on the current treatment landscape for patients with AYA ALL, the panel discusses clinical practices and treatment decisions based on age.
Advertisement
Video content above is prompted by the following questions:
- What is the current treatment landscape for AYA ALL?
- How has the treatment landscape evolved over time?
- What is the role of asparaginase in the treatment of ALL in adolescents and young adults (AYA)?
- What are some challenges in treating this patient population?
- When treating AYA ALL in your practice, do you usually consider a pediatric-inspired regimen or an adult-inspired regimen?
- Have you noticed a difference in outcomes between pediatric and adult regimens?
- Have you noticed a difference in outcomes between pediatric and adult regimens?
Advertisement
Related to this article
The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
How Bispecific T-Cell Engager Therapy Works and Why HLA Status Is Non-Negotiable
3
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
4
FDA Accepts NDA for Varegacestat in Desmoid Tumors
5